Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Payables (2022 - 2025)

Historic Payables for Lucid Diagnostics (LUCD) over the last 4 years, with Q3 2025 value amounting to $24.6 million.

  • Lucid Diagnostics' Payables rose 10135.18% to $24.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.6 million, marking a year-over-year increase of 10135.18%. This contributed to the annual value of $21.4 million for FY2024, which is 2044.85% up from last year.
  • Per Lucid Diagnostics' latest filing, its Payables stood at $24.6 million for Q3 2025, which was up 10135.18% from $27.7 million recorded in Q2 2025.
  • Lucid Diagnostics' 5-year Payables high stood at $34.9 million for Q1 2025, and its period low was $1.1 million during Q3 2022.
  • For the 4-year period, Lucid Diagnostics' Payables averaged around $15.0 million, with its median value being $14.2 million (2023).
  • Its Payables has fluctuated over the past 5 years, first skyrocketed by 147943.26% in 2023, then plummeted by 3148.85% in 2024.
  • Quarter analysis of 4 years shows Lucid Diagnostics' Payables stood at $1.4 million in 2022, then surged by 1129.51% to $17.8 million in 2023, then rose by 20.45% to $21.4 million in 2024, then grew by 14.69% to $24.6 million in 2025.
  • Its last three reported values are $24.6 million in Q3 2025, $27.7 million for Q2 2025, and $34.9 million during Q1 2025.